Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab

NCT02559622 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Secukinumab
OTHER: Placebo
OTHER: Placebo
DRUG: Secukinumab

Sponsor

Novartis Pharmaceuticals